
CLAIMS

WE CLAIM:

1. Use of a therapeutically effective amount of cetuximab and a KRAS G12C inhibitor of formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject, wherein the cancer is lung, colorectal, squamous cell carcinoma, or rectum adenocarcinoma associated with a KRas G12C mutation.

2. The use according to claim 1, wherein the cetuximab and the KRAS G12C inhibitor are to be administered on the same day.


3. The use according to claim 1, wherein the cetuximab and the KRAS G12C inhibitor are to be administered on different days.


4. The use according to claim 1, wherein the KRas G12C inhibitor is to be administered at a maximum tolerated dose.

5. The use according to claim 1, wherein the cetuximab and the KRAS G12C inhibitor are each to be administered at a maximum tolerated dose.



6. The use according to any one of claims 1-5, wherein the therapeutically effective amount of the combination of the cetuximab and the KRAS G12C inhibitor results in an increased duration of overall survival, an increased duration of progression free survival, an increase in tumor

growth regression, an increase in tumor growth inhibition or an increased duration of stable disease in the subjects relative to treatment with only the KRas G12C inhibitor.

7. A pharmaceutical composition, comprising a therapeutically effective amount of a combination of cetuximab and a KRas G12C inhibitor of Formula  or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient for use in the treatment of cancer, wherein the cancer is lung, colorectal, squamous cell carcinoma, or rectum adenocarcinoma associated with a KRas G12C mutation.

8. A method for inhibiting KRas G12C activity in a cancer cell in vitro or ex vivo, comprising contacting the cell in which inhibition of KRas G12C activity is desired with an effective amount of cetuximab and a KRas G12C inhibitor compound of a Formula , pharmaceutical compositions or pharmaceutically acceptable salts thereof, wherein the cetuximab synergistically increases the sensitivity of the cancer cells to the KRas G12C inhibitor, wherein the cancer cell is a cell in lung, colorectal, squamous cell carcinoma, or rectum adenocarcinoma associated with a KRas G12C mutation.

9. The use according to any one of claims 1-6 or the method according to claim 8, wherein the cetuximab synergistically increases the sensitivity of the cancer cells to the KRas G12C inhibitor.

10. A method for increasing the sensitivity of a cancer cell in vitro or ex vivo to a KRas G12C inhibitor compound of Formula ,comprising administering to a subject undergoing KRas G12C treatment with a compound of Formula  or a pharmaceutically acceptable salt thereof, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, a therapeutically effective amount of cetuximab, wherein the pan ErbB family inhibitor synergistically increases the sensitivity of the cancer cell to the KRas G12C inhibitor, wherein the cancer is lung, colorectal, squamous cell carcinoma, or rectum adenocarcinoma associated with a KRas G12C mutation.

11. The use according to any one of claims 1-6, wherein the therapeutically effective amount of the KRas G12C inhibitor is between 0.01 to 100 mg/kg per day.

12. The use according to claim 11, wherein the therapeutically effective amount of the KRas G12C inhibitor is between 0.1 to 50 mg/kg per day.

13. The use according to any one of claims 1-6, wherein the therapeutically effective amount of the cetuximab is between 0.01 to 100 mg/kg per day.


14. The use according to claim 13, wherein the therapeutically effective amount of the cetuximab is between 0.1 to 50 mg/kg per day.

15. The use according to claim 1, wherein the KRas G12C-associated cancer is non-small cell lung cancer.

16. The use according to claim 1, wherein the KRas G12C-associated cancer is colorectal cancer.

17. A kit comprising the pharmaceutical composition of claim 7.

18. A kit comprising: a) a pharmaceutical composition comprising cetuximab and b) a pharmaceutical composition comprising a KRas G12C inhibitor of formula:



or a pharmaceutically acceptable salt thereof
for treating cancer in a subject, wherein the cancer is lung, colorectal, squamous cell carcinoma, or rectum adenocarcinoma associated with a KRas G12C mutation.

19. The kit according to claim 17 or 18, further comprising an insert with instructions for administration of the pharmaceutical composition(s).